KR20130135104A - Compounds of catechol grafted copolymers and its appication for hemostatic and anti-adhesive materials - Google Patents

Abstract

Provided are catechol grafted copolymers, copolymer cross-linked copolymer compounds, functional matrix compounds and a method for producing the same. In a more particular way, the present invention relates to catechol grafted copolymers characterized in comprising: a polyvinyl copolymer organization made up of polyvinyl copolymers in which vinyl compounds are bonded or copolymer in which main chain formable compounds are connected to polyvinyl copolymers; and a catechol derivative grafted in the polyvinyl copolymer organization.

Description

Catechol graft copolymers, copolymer compositions crosslinked with the copolymer, functional glue matrix compositions, and methods for preparing the same {Compounds of catechol grafted copolymers and its appication for hemostatic and anti­adhesive materials}

The present invention relates to a catechol graft copolymer, a copolymer composition crosslinked with the copolymer, a functional glue matrix composition, and a method for producing the same. More specifically, a polyvinyl copolymer copolymer composed of a polyvinyl copolymer or a copolymer in which a main chain formable compound is bonded to a polyvinyl copolymer, wherein the vinyl compounds are bound; And a catechol derivative grafted to the polyvinyl copolymer matrix, a catechol graft copolymer, a crosslinked copolymer composition in which the catechol graft copolymer is crosslinked with a natural / synthetic biopolymer, and The present invention relates to a functional glue matrix composition in which a film sheet having hemostatic and anti-adhesion properties is bonded to a copolymer film prepared in the form of a crosslinked copolymer composition.

The ideal wound coating should provide an environment where wound healing can be done quickly and effectively, and should be able to minimize scarring after the wound has healed. For this purpose, the wound coating should have the functions of hemostasis, exudate absorption, pain relief, drug administration, protection from external stimuli, infection prevention, and concealment.

The most commonly used wound coating is formed of an adhesive band and a gauze in the center of the wound. A common gauze dressing is easy to absorb the exudates but has no protection against bacterial infection. In addition to delaying wound healing, the dressing agent adheres to the wound surface, resulting in damage to new tissues during exchange, and is difficult to remove.

Research and development in the field of tissue adhesives, including sealants and hemostats, is growing rapidly. With fibrin sealants approved by the US FDA in 1998, new tissue adhesives are constantly being developed each year. Such tissue adhesives are in the spotlight as a material that can replace techniques such as suture, clip surgery, and moxibustion that are conventionally used in surgical or medical surgery.

Existing surgical techniques, such as sutures, have strong tensile strength, but have problems such as causing pain and removal after the procedure. On the other hand, tissue adhesives have a number of advantages, such as fast adhesion time, ease of use, and no need for removal after the procedure. However, tissue adhesives have limitations of low adhesiveness and tensile strength and adhesion in the presence of moisture. Research to overcome the limitations of these tissue adhesives is continuing.

In general, tissue adhesives are used in various areas such as skin, blood vessels, digestive organs, cranial nerves, plastic surgery, orthopedic surgery, but each requires different characteristics, but mainly requires the following characteristics. That is, 1) it must be rapidly bonded at room temperature and atmospheric pressure even in the presence of moisture, 2) it must be non-toxic and sterilized, 3) it must adhere to the wound surface and maintain sufficient mechanical strength, 4) biodegradation Sexual and hemostatic effects should be possible, and 5) effective for biological healing.

Tissue adhesives currently being commercialized and / or put into practice include cyanoacrylate instant adhesives, fibrin glues, gelatin glues, and polyurethane-based adhesives.

Such cyanoacrylate-based tissue adhesives are currently commercialized as products such as Dermabond (Johnson & Johnson) and Indermil (US Surgical). Such cyanoacrylate-based tissue adhesive has a single material, which is cured by moisture at room temperature without an initiator in a short time, has an advantage in that its appearance is transparent, and its adhesive strength is large, but it is weak in impact and inferior in heat resistance. In addition, it is very toxic and is rarely used at present and is partially used in clinical practice in countries other than the United States, but its use is limited due to some tissue toxicity and vulnerability.

Fibrin glue adhesive can be fixed by applying artificial glue or fascia in the otorhinolaryngology area when the cerebrospinal fluid is leaked after the nasal surgery, and by applying glue to prevent perforation during septal surgery. In some cases, fibrin glue may be applied for hemostasis and pain relief after tonsillectomy. However, due to the peculiarities of human tissues, there are still risky limitations of infection without showing complete biocompatibility or safe adhesion.

In addition, gelatin glue was developed by crosslinking with gelatin-resorcinol-formalin (GRF) as a tissue adhesive derived from a living body. In addition, tissue adhesives such as gelatin-glutaaldehyde have been developed, but tissue adhesion is high, but formalin or glutaaldehyde, which is used as a crosslinking agent, has a disadvantage of causing tissue toxicity by causing crosslinking reaction with proteins in vivo.

(Patent Document 0001) Domestic Publication No. 10-2011-0025530

The present invention has been made to solve the above problems, in accordance with an embodiment of the present invention, a functional glue matrix combined with a catechol graft copolymer, a crosslinked product thereof, and a film sheet having an anti-adhesion agent and a hemostatic composition Through the composition, it is possible to provide a composition having excellent biocompatibility and a crosslinked product formed through crosslinking of catechol functional groups having excellent tissue adhesion. In addition, hyaluronic acid is used to provide a functional medical bioadhesive that can not only prevent adhesion to other sites at the adhesion site but also provide a secondary hemostatic effect through sodium alginate.

A first object of the present invention is a polyvinyl copolymer copolymer composed of a polyvinyl copolymer or a copolymer in which a main chain formable compound is bonded to a polyvinyl copolymer, wherein the vinyl compounds are bound; And it can be achieved as a catechol graft copolymer, characterized in that it comprises a catechol derivative grafted to the polyvinyl copolymer matrix.

The polyvinyl copolymer matrix may be a compound of Formula 1 below.

[Formula 1]

In Formula 1,

X and Z are vinyl compounds,

X is greater than 0 and less than 100 wt% and Z is greater than 0 and less than 100 wt% with respect to the total weight of the polyvinyl copolymer copolymer.

The vinyl compound is 2-hydroxyethyl methacrylate (HEMA, 2-hydroxyethyl methacrylate), 2-hydroxyethyl acrylate (HEA, 2-hydroxyethyl acrylate), 2-dimethylaminoethyl methacrylate (DMAEMA, 2 -(dimethylamino) ethyl methacrylate), 2-diethylaminoethyl methacrylate (DEAEMA, 2- (diethylamino) ethyl methacrylate), tert-butylmethacrylate (t-BMA, tert-butylmethacrylate), 2-aminoethyl 2-Aminoethyl methacrylate (AEM), methyl methacrylate, ethyl methacrylate, butyl methacrylate, isobutyl methacrylate, hexyl methacrylate, isodecyl methacrylate, lryl methacrylate, phenyl At least one polymer selected from methacrylate, methyl acrylate, isopropyl acrylate, isobutyl acrylate and octadecyl acrylate It can be made.

General formula of Formula 1 may be represented by the following formula (2).

(2)

In Formula 2, a is 20 to 2000,

Y is H, CH ₃ , CH ₂ CH ₃ Lt; / RTI >

R is either COO or CONH,

b is an integer from 0 to 5,

P is H, hydroxy (OH), amine (NH ₂ ), tertiary amine [N (CH ₃ ) ₂ , N (CH ₂ CH ₃ ) ₂ or N (CH ₂ CH ₂ CH ₃ ) ₂ ], CH _{3 ,} C (CH ₃ ) ₃ and C (CH ₂ CH ₃ ) ₃ .

The copolymer in which the main chain-forming compound is bonded to the polyvinyl copolymer may be formed of the following Chemical Formula 3.

(3)

In Formula 3,

A is a main chain formable compound,

X and Z are vinyl compounds,

X is more than 0 and less than 100% by weight and Z is more than 0 and less than 100% by weight relative to the total weight of the polyvinyl copolymer.

The main chain formable compound may be selected from the group consisting of polyethylene glycol, polypropylene oxide, polycaprolactone, polylactic acid, pluronic, polyglycolic acid, methoxy polyethylene glycol, polylactic glycol, polylactic and polyglycol. At least one selected from among the recall may be characterized.

The vinyl compound is 2-hydroxyethyl methacrylate (HEMA, 2-hydroxyethyl methacrylate), 2-hydroxyethyl acrylate (HEA, 2-hydroxyethyl acrylate), 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate), 2-diethylaminoethylmethacrylate (DEAEMA, 2- (diethylamino) ethyl methacrylate), tert-butylmethacrylate (t-BMA, tert-butylmethacrylate), 2-amino Ethyl methacrylate (AEM, 2-aminoethyl methacrylate), methyl methacrylate, ethyl methacrylate, butyl methacrylate, isobutyl methacrylate, hexyl methacrylate, isodecyl methacrylate, lolyl methacrylate, At least one polymer selected from phenyl methacrylate, methyl acrylate, isopropyl acrylate, isobutyl acrylate and octadecyl acrylate. You can do it with gong.

General structural formula of Formula 3 may be represented by the following formula (4).

[Chemical Formula 4]

In Chemical Formula 4, a is 20 to 2000.

Y is H, CH ₃ , CH ₂ CH ₃ Lt; / RTI >

R is either COO or CONH,

b is an integer from 0 to 5,

P is H, hydroxy (OH), amine (NH ₂ ), tertiary amine [N (CH ₃ ) ₂ , N (CH ₂ CH ₃ ) ₂ or N (CH ₂ CH ₂ CH ₃ ) ₂ ], CH _{3 ,} C (CH ₃ ) ₃ and C (CH ₂ CH ₃ ) ₃ ,

The molecular weight of A is 200-50,000 Da.

The polyvinyl copolymer matrix contains 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) and tert-butylmethacrylate (t-BMA, tert-butylmethacrylate) It may be characterized by having a molecular weight of 1,000 ~ 100,000 grams.

The catechol graft copolymer may be a compound composed of the following Chemical Formula 5.

[Chemical Formula 5]

X is a polyvinyl copolymer matrix,

Y is a catechol derivative,

l: m is the weight ratio of X and Y, with respect to the total weight of the catechol graft copolymer, X is greater than 0 to less than 100% by weight and Y is greater than 0 to less than 100% by weight.

The catechol derivatives are 2-chloro-3 ', 4'-dihydroxyacetophenone, 2-bromo-3', 4'-dihydroxyacetophenone, 2-iodide-3 ', 4' -Dihydroxyacetophenone, dopamine, caffeic acid, garlic acid, chlorogenic acid, (-)-epicatechin, (-)-epicatechin gallate, melanin, tannin, flavonoids, cyanidins, dihydroquercetin, oron, di Hydromyricetin, delphinidin, mycetin, quercetin, (-)-epicalocatechin-3-gallate, catechin, luteolin, norepinephrine and epinephrine may be characterized in that any one or more selected.

The catechol derivative may be a compound consisting of the following formula (6) or formula (7).

[Chemical Formula 6]

[Formula 7]

In the above formula (6) or (7)

L is Cl, Br or I,

n is an integer from 1 to 12.

A second object of the present invention, step 1 of adding a reaction solvent to the polyvinyl copolymer and reacted at 60 ℃ to 80 ℃ or more for 12 hours or more to prepare a polyvinyl copolymer matrix; And a step 2 of mixing the polyvinyl copolymer matrix prepared in Step 1, the catechol derivative, and the organic solvent having 1 to 7 carbon atoms, reacting at 20 ° C. to 80 ° C. for at least 24 hours, and then purifying them. It can be achieved as a method for producing a catechol graft copolymer characterized by.

The polyvinyl copolymer of step 1, 2-hydroxyethyl methacrylate (HEMA, 2-hydroxyethyl methacrylate), 2-hydroxyethyl acrylate (HEA, 2-hydroxyethyl acrylate), 2-dimethylaminoethyl meth Acrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate), 2-diethylaminoethylmethacrylate (DEAEMA, 2- (diethylamino) ethyl methacrylate), tert-butylmethacrylate (t-BMA, tert-butylmethacrylate ), 2-aminoethyl methacrylate (AEM, 2-aminoethyl methacrylate), methyl methacrylate, ethyl methacrylate, butyl methacrylate, isobutyl methacrylate, hexyl methacrylate, isodecyl methacrylate, At least one selected from lauryl methacrylate, phenyl methacrylate, methyl acrylate, isopropyl acrylate, isobutyl acrylate and octadecyl acrylate It may be characterized in that the molecule is copolymerized.

The reaction solvent may be any one of tetrahydrofuran, toluene, benzene, dichloromethane and ethanol.

The polyvinyl copolymer matrix may be any one of the following 1-3.

1) Molecular weight of 1,000 to 100,000 grams per mole of 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) combined with tert-butylmethacrylate (t-BMA) Copolymers;

2) a copolymer having a molecular weight of 1,000 to 100,000 grams per mole of 2-hydroxyethyl methacrylate (HEMA); or

3) Copolymer having a molecular weight of 1,000 to 100,000 grams per mole in which tert-butylmethacrylate (t-BMA, tert-butylmethacrylate) is bonded.

The catechol derivatives are 2-chloro-3 ', 4'-dihydroxyacetophenone, 2-bromo-3', 4'-dihydroxyacetophenone, 2-iodide-3 ', 4' -Dihydroxyacetophenone, dopamine, caffeic acid, garlic acid, chlorogenic acid, (-)-epicatechin, (-)-epicatechin gallate, melanin, tannin, flavonoids, cyanidins, dihydroquercetin, oron, di Hydromyricetin, delphinidin, mycetin, quercetin, (-)-epicalocatechin-3-gallate, catechin, luteolin, norepinephrine and epinephrine may be characterized in that any one or more selected.

The catechol graft copolymer may be a compound consisting of the following formula (5).

[Chemical Formula 5]

X is a polyvinyl copolymer matrix,

Y is a catechol derivative,

1: m is the weight ratio of X and Y, with respect to the total weight of the catechol graft copolymer, X is greater than 0 to less than 100% by weight and Y is greater than 0 to less than 100% by weight.

A third object of the present invention, the catechol graft copolymer according to the first object mentioned above; And synthetic / natural polymers that are crosslinked with the catechol graft copolymer.

The synthetic / natural polymer, hyaluronic acid, sodium alginate, potassium alginate, chitosan, collagen, lysine (Lysine), polyethyleneimine (PEI, polyethyleneimine), glutathione (GSH), dextran (Dextran), carboxymethyl cellulose (CMC, carboxymethyl cellulose), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC, hydroxypropyl cellulose), glucose, gum arabic, ethanol, sodium casein, agar powder, glycerin, cellulose acetate Stearic acid, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium methyl cellulose, methyl cellulose, purified shellac, ethyl cellulose (Ethylcelluose), sodium alginate, sodium lauryl sulfate (SLS, Sodium Lauryl Sulfate), magnesium (Maganesium) ), Microcrystalline cellulose, starch, hydroxycellulose, Selected from hydroxypropyl starch, polyvinyl alcohol, hydroxymethyl cellulose, sorbitol, hydroxyethyl starch, propo, polyethylene glycol (PEG) and Pluronic It may be characterized as one.

The molecular weight of the synthetic / natural polymer may be characterized in that 1,000 to 4,000,000 Da.

The fourth object of the present invention, 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) and tert- butyl methacrylate (t-BMA, tert-butylmethacrylate), molecular weight regulators and initiators Step 1 to prepare a polyvinyl copolymer matrix by addition; Preparing a catechol graft copolymer to which the catechol derivative is grafted by reacting the catechol derivative with the polyvinyl copolymer matrix prepared in step 1; And a step 3 of crosslinking the catechol graft copolymer prepared in step 2 with the synthetic / natural biopolymer to prepare a crosslinked copolymer composition.

In step 1, the polyvinyl copolymer matrix, 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) and tert-butylmethacrylate (t-BMA, tert-butylmethacrylate) To 100 parts by weight, it may be prepared by adding 0.15 to 1 parts by weight of the molecular weight regulator and 0.05 to 0.3 parts by weight of the initiator.

In step 2, it may be characterized in that the reaction for 24 to 50 hours at a temperature of 60 ℃ to 90 ℃ under ethanol solvent.

In the step 3, it may be characterized in that the reaction for 10 to 12 hours at a temperature of 50 ℃ to 60 ℃ under TBS (Trizma based solution) solvent.

The fifth object of the present invention is a copolymer film conjugated with a catechol in the form of a film freeze-dried crosslinked copolymer composition according to the third object; And it can be achieved as a functional glue matrix composition comprising a film sheet bonded to at least one of the upper and lower surfaces of the copolymer film.

The film sheet may be characterized by comprising a component having anti-adhesion or hemostatic properties.

The film sheet, hyaluronic acid, sodium alginate, potassium alginate, chitosan, collagen (collagen), lysine (Lysine), polyethyleneimine (PEI, polyethyleneimine), glutathione (GSH), dextran (Dextran), carboxymethyl cellulose (CMC carboxymethyl cellulose), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC, hydroxypropyl cellulose), glucose, gum arabic, ethanol, casein sodium, agar powder, glycerin, cellulose acetate, stearic acid, Sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium methyl cellulose, methyl cellulose, purified shellac, ethyl cellulose (Ethylcelluose), sodium alginate, sodium lauryl sulfate (SLS), sodium lauryl sulfate (Maganesium), Microcrystalline cellulose, starch, hydroxycellulose, hydroxy At least one of hydroxypropyl starch, polyvinyl alcohol, hydroxymethyl cellulose, sorbitol, hydroxyethyl starch, propo, polyethylene glycol (PEG) and Pluronic It may be characterized by consisting of a composition of.

The molecular weight of the film sheet may be characterized in that 1,000 to 4,000,000 Da.

The film sheet may be characterized by consisting of hyaluronic acid, sodium alginate or potassium alginate.

Therefore, as described, according to one embodiment of the present invention, the catechol graft copolymer, its crosslinked product, and excellent biocompatibility through the functional glue matrix composition combined with the film sheet having the anti-adhesive agent and the hemostatic composition, Crosslinked materials formed through crosslinking of cole functional groups have the effect of generating excellent tissue adhesion.

In addition, hyaluronic acid may be used to prevent adhesion to other sites at the adhesion site as well as to provide a secondary hemostatic effect through sodium alginate. In particular, it can be used as a material for tissue adhesion or hemostasis using such a composition, there is an advantage that the wound can be healed by adhering to a wound, such as a wound, burn, or cut.

In addition, the medical adhesive through the material having a catechol functional group is a moisture-resistant medical biological tissue adhesive that has a stronger adhesion ability than the conventional adhesive material in the wet environment, such as the human body, and shows adhesion again when moisture is again given. It has the effect of providing a manufacturing method.

Figure 1a shows a cross-sectional view of a catechol conjugated copolymer film according to an embodiment of the present invention.
1B illustrates a cross-sectional view of a functional glue matrix in which a catechol conjugated copolymer film and a film sheet are combined according to an embodiment of the present invention.
Figure 2 shows the 1H NMR results of the polyvinyl copolymer matrix according to an embodiment of the present invention.
Figure 3 shows the 1H NMR results of the catechol graft copolymer grafted catechol derivatives in the polyvinyl copolymer according to an embodiment of the present invention.
Figure 4 shows the 1H NMR results of the crosslinked copolymer composition according to an embodiment of the present invention.
5 is a photograph for showing the adhesion of the crosslinked copolymer composition according to an embodiment of the present invention.
Figure 6 shows the results of measuring the adhesion of the crosslinked copolymer composition according to an embodiment of the present invention.
Figure 7 shows the adhesion over time of the crosslinked copolymer composition according to an embodiment of the present invention.
Figure 8 is a photograph showing the hemostatic effect in the liver, kidney and heart of the crosslinked copolymer composition according to an embodiment of the present invention.
Figure 9 is a photograph showing the hemostatic effect in the vein of the crosslinked copolymer composition according to an embodiment of the present invention.
10 is a result showing the adhesive force of the functional glue matrix combined with the catechol conjugated copolymer film and the film sheet according to an embodiment of the present invention.
Figure 11 is a result showing the adhesive force over time of the functional glue matrix combined with the catechol conjugated copolymer film and the film sheet according to an embodiment of the present invention.

Hereinafter, the present invention will be described in detail.

The present invention provides a catechol graft copolymer in which a catechol derivative is grafted to a polyvinyl copolymer matrix; Ii) a crosslinked copolymer composition having hemostatic and anti-adhesion properties in which the catechol graft copolymer and the synthetic / natural polymer are crosslinked; Iii) to a functional glue matrix composition in which a film sheet having an anti-adhesion agent and a hemostatic composition is added to a catechol-conjugated copolymer film prepared in the form of a crosslinked copolymer composition.

In the anti-adhesion agent and hemostatic composition according to an embodiment of the present invention, a mixture of hyaluronic acid and sodium alginate has anti-adhesion and hemostatic effects.

In another aspect, the present invention can be prepared in the form of a film cross-linked catechol graft copolymer in the form of a film, and bonded to a film sheet having an anti-adhesion agent and hemostatic composition to prepare a functional glue matrix.

The functional glue matrix is prepared according to a conventional method, the copolymer film in the form of a flat sheet of the crosslinked copolymer composition according to an embodiment of the present invention, and wetted by spraying an appropriate amount of water on one or more sides of the copolymer film. The film sheet having the anti-adhesion agent and the hemostatic composition may be attached to the wet surface. In this case, as the film sheet, biopolymers, synthetic polymers, synthetic / biopolymers, copolymers not containing catechol derivatives, general-purpose films (PP, PS, PET, PE, PVC) and the like are used in the art. Of course it can be used.

One embodiment of the present invention, specifically, iii) catechol graft copolymer grafted catechol derivative to the polyvinyl copolymer matrix; Ii) a crosslinked copolymer composition having hemostatic and anti-adhesion properties in which the catechol graft copolymer and the synthetic / natural polymer are crosslinked; Iii) a functional glue matrix composition in which a film sheet is added to a copolymer film prepared in the form of a crosslinked copolymer.

Hereinafter, the structure of the catechol graft copolymer grafted catechol derivative to the polyvinyl copolymer matrix according to an embodiment of the present invention. The catechol graft copolymer is prepared by grafting a catechol derivative to a polyvinyl copolymer matrix. First, the configuration of the polyvinyl copolymer matrix will be described. Polyvinyl-based copolymer matrix according to an embodiment of the present invention, the vinyl-based compound is composed of a polyvinyl-based copolymer, or the main chain formable compound is bonded to the polyvinyl-based copolymer in which the vinyl-based compound is bonded Can be formed.

Polyvinyl-based copolymer matrix according to an embodiment of the present invention may be a compound represented by the following formula (1) or (2).

[Formula 1]

In Formula 1, X and Z are generic names of vinyl compounds as follows.

Representative vinyl compounds represented by the formula (1) is 2-hydroxyethyl methacrylate (HEMA, 2-hydroxyethyl methacrylate), 2-hydroxyethyl acrylate (HEA, 2-hydroxyethyl acrylate), 2-dimethylaminoethyl methacryl (DMAEMA, 2- (dimethylamino) ethyl methacrylate), 2-diethylaminoethylmethacrylate (DEAEMA, 2- (diethylamino) ethyl methacrylate), tert-butylmethacrylate (t-BMA, tert-butylmethacrylate) , 2-aminoethyl methacrylate (AEM, 2-aminoethyl methacrylate) may be any one or more polymers selected from.

Regarding the total weight of the polyvinyl copolymer copolymer, X in Chemical Formula 1 is greater than 0 to less than 100 wt%, and Z is greater than 0 to less than 100 wt%.

General formula of Formula 1 is represented by the formula (2).

(2)

In Formula 2, a is 20 to 2000,

Y is H, CH ₃ , CH ₂ CH ₃ Lt; / RTI >

R is either COO or CONH,

b is an integer from 0 to 5,

P is H, hydroxy (OH), amine (NH ₂ ), tertiary amine [N (CH ₃ ) ₂ , N (CH ₂ CH ₃ ) ₂ or N (CH ₂ CH ₂ CH ₃ ) ₂ ], CH _{3 ,} C (CH ₃ ) ₃ and C (CH ₂ CH ₃ ) ₃ .

In addition, as mentioned above, the polyvinyl copolymer matrix for constituting the catechol graft copolymer may be formed by combining a main chain formable compound with the aforementioned polyvinyl copolymer.

As such a main chain-formable compound, polyethylene, polystyrene, polyethylene glycol (PEG), polypropylene oxide, methoxy polyethylene glycol, polyglycol, pluronic and the like can be used. In this case, the main chain-forming compound may be a polyvinyl copolymer is grafted in irregular or block shape to the main chain.

As described above, the polyvinyl-based copolymer parent in which the polyvinyl-based copolymer is bonded to the main chain-forming compound may be a compound represented by the following Chemical Formula 3.

(3)

In Formula 3,

A is a main chain formable compound, which is polyethylene glycol, polypropylene oxide, polycaprolactone, polylactic acid, pluronic, polyglycolic acid, methoxy polyethyleneglycol, polylactic glycol, polylactic and poly One compound selected from glycols forms the graft copolymer.

In Formula 3, X and Z are generic names of vinyl compounds as follows.

The vinyl compound, which is one component of Formula 3, is typically 2-hydroxyethyl methacrylate (HEMA, 2-hydroxyethyl methacrylate), 2-hydroxyethyl acrylate (HEA, 2-hydroxyethyl acrylate), or 2-dimethyl. Aminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate), 2-diethylaminoethyl methacrylate (DEAEMA, 2- (diethylamino) ethyl methacrylate), tert-butylmethacrylate (t-BMA, tert-butylmethacrylate), 2-aminoethyl methacrylate (AEM, 2-aminoethyl methacrylate) may be any one or more polymers selected from.

With respect to the total weight of the polyvinyl copolymer in Formula 3, X is greater than 0 to less than 100% by weight, Z is greater than 0 to less than 100% by weight.

General structural formula of Formula 3 is represented by the following formula (4).

[Chemical Formula 4]

In Chemical Formula 4, a is 20 to 2000.

Y is H, CH ₃ , CH ₂ CH ₃ Lt; / RTI >

R is either COO or CONH,

b is an integer from 0 to 5,

P is H, hydroxy (OH), amine (NH ₂ ), tertiary amine [N (CH ₃ ) ₂ , N (CH ₂ CH ₃ ) ₂ or N (CH ₂ CH ₂ CH ₃ ) ₂ ], CH _{3 ,} C (CH ₃ ) ₃ and C (CH ₂ CH ₃ ) ₃ . The molecular weight of A is 200 to 50,000 Da.

It can be seen that the polyvinyl copolymer matrix represented by Chemical Formulas 1 to 4 has a form in which a polyvinyl copolymer or a polyvinyl copolymer is bonded using a main chain-forming polymer as a main chain. It is preferable that the polyvinyl copolymer matrix of Formula 1 or 4 has a molecular weight of 1,000 to 400,000 grams per mole.

Iii) a catechol graft copolymer grafted with a catechol derivative on a polyvinyl copolymer matrix according to an embodiment of the present invention using the polyvinyl copolymer matrix represented by Chemical Formulas 1 to 4; Ii) a crosslinked copolymer composition having hemostasis and anti-adhesion properties in which the catechol graft copolymer and the synthetic / natural polymer are crosslinked; The combined functional glue matrix can be made. Functional glue matrix according to an embodiment of the present invention exhibits an adhesive force having excellent hemostatic and anti-adhesion properties.

The following Chemical Formula 5 shows the chemical formula of the catechol graft copolymer in which a catechol derivative is grafted to the polyvinyl copolymer matrix, and shows the substitution rate of the polyvinyl copolymer matrix contained in the catechol graft copolymer.

[Chemical Formula 5]

X is a polyvinyl copolymer matrix,

Y is a catechol derivative,

1: m means the weight ratio of X and Y, X is greater than 0 to less than 100%, Y is greater than 0 to less than 100% by weight relative to the total weight of the catechol graft copolymer.

As described above, the vinyl compound constituting the polyvinyl copolymer matrix in Chemical Formula 5 may be 2-hydroxyethyl methacrylate (HEMA, 2-hydroxyethyl methacrylate), 2-hydroxyethyl acrylate (HEA, 2-hydroxyethyl acrylate), 2-dimethylaminoethyl methacrylate (DMAEMA), 2-diethylaminoethyl methacrylate (DEAEMA, 2- (diethylamino) ethyl methacrylate), tert- It may be a copolymer obtained by copolymerizing any one or more polymers selected from butyl methacrylate (t-BMA, tert-butylmethacrylate) and 2-aminoethyl methacrylate (AEM, 2-aminoethyl methacrylate).

The polyvinyl copolymer matrix is most preferably 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) and tert-butylmethacrylate (t-BMA, tert-butylmethacrylate).

The catechol derivative in Formula 5 is 2-chloro-3 ', 4'-dihydroxyacetophenone, 2-bromo-3', 4'-dihydroxyacetophenone, 2-iodine-3 ', 4' -Dihydroxyacetophenone, dopa, dopamine, caffeic acid, garlic acid, chlorogenic acid, (-)-epicatechin, (-)-epicatechin gallate, melanin, tannin, flavonoids, cyanidins, dihydrokercetin, oron , Dihydromyricetin, delphinidin, myrcetin, quercetin, (-)-epicalocatechin-3-gallate, (-)-epigallocatechin, (-)-epigallocatechin gallate, catechin, luteolin , Norepinephrine, epinephrine and the like can be used.

In addition, the catechol derivative is most preferably 2-chloro-3 ', 4'-dihydroxyacetophenone ((2-chloro-3', 4'-dihydroxyacetophenone).

Specifically, the catechol derivative may be a compound represented by the following Chemical Formula 6 or Chemical Formula 7.

[Chemical Formula 6]

[Formula 7]

In the above formula (6) or (7)

L is Cl, Br or I,

n is an integer from 1 to 12.

Next, ii) preparation of a crosslinked copolymer composition (catechol graft copolymer crosslinked) having hemostatic and anti-adhesion properties in which the catechol graft copolymer and the synthetic / natural polymer are cross-linked according to an embodiment of the present invention. Let's explain how.

The catechol graft copolymer crosslinked product according to an embodiment of the present invention is 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) and tert-butyl methacrylate (t-BMA, tert- butylmethacrylate), a molecular weight modifier and an initiator are added to prepare a polyvinyl copolymer matrix; Preparing a catechol graft copolymer to which the catechol derivative is grafted to the polyvinyl copolymer matrix by reacting the catechol derivative with the polyvinyl copolymer matrix prepared in step 1; And step 3 preparing a crosslinked copolymer composition through crosslinking of the catechol graft copolymer prepared in step 3 with the synthetic / natural polymer.

The polyvinyl copolymer matrix of the present invention is 100 parts by weight of 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) and tert-butylmethacrylate (t-BMA, tert-butylmethacrylate). With respect to the adhesiveness, it is preferable to prepare by adding 0.1 to 4 parts by weight, preferably 0.15 to 1 part by weight, and 0.01 to 0.3 parts by weight of the initiator, preferably 0.05 to 0.25 parts by weight.

Step 2 is preferably carried out for 24 to 50 hours, preferably 24 to 48 hours at a temperature of 60 to 90 ℃ in ethanol solvent. If the temperature is too low, the reactivity is too low. If the temperature is too high, a crosslinking reaction will occur and the desired product will not be obtained.

Step 3 is preferably carried out for 10 to 15 hours, preferably 10 to 12 hours at a temperature of 50 to 60 ℃ in a Trizma based solution (TBS) solvent. If the temperature is too low, the reactivity is too low. If the temperature is too high or the crosslinking time is too long, the crosslinking reaction will occur too much to obtain the desired product.

Next, iii) the composition of the functional glue matrix composition in which a film sheet is added to the copolymer film prepared in the form of a film of the crosslinked copolymer according to an embodiment of the present invention. Figure 1a is a cross-sectional view of a catechol conjugated copolymer film according to an embodiment of the present invention, Figure 1b is a catechol conjugated copolymer film and a film sheet according to an embodiment of the present invention Shows a cross-sectional view of the functional glue matrix to which is bonded.

This functional glue matrix composition comprises a copolymer film 2 having a catechol conjugated by drying the crosslinked copolymer composition (catechol graft copolymer crosslinked product) described above as shown in FIGS. 1A and 1B; And a film sheet 1 bonded to at least one of the upper and lower surfaces of the copolymer film and having a composition having hemostatic and anti-adhesion properties.

Film sheet having a composition having such a hemostatic and anti-adhesion properties is hyaluronic acid, sodium alginate, potassium alginate, chitosan, collagen, lysine (Lysine), polyethyleneimine (PEI, polyethyleneimine), glutathione (GSH), dextran (Dextran), carboxymethyl cellulose (CMC), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC, hydroxypropyl cellulose), glucose, gum arabic, ethanol, sodium casein, agar powder , Glycerin, Phosphate Acetate, Stearic Acid, Sodium Carboxymethyl Cellulose, Sodium Carboxymethyl Cellulose, Sodium Methyl Cellulose, Methyl Cellulose, Purified Shellac, Ethylcelluose, Sodium Alginate, Sodium Lauryl Sulfate (SLS, Sodium) Lauryl Sulfate), Magnesium, Microcrystalline Cellulite Rhose, starch, hydroxycellulose, hydroxypropyl starch, polyvinyl alcohol, hydroxymethyl cellulose, sorbitol, hydroxyethyl starch, propo, polyethylene glycol (PEG) And Pluronic may be composed of at least one composition. It is preferably composed of hyaluronic acid, sodium alginate or potassium alginate. Moreover, it is preferable that the molecular weight of a film sheet is 1,000-4,000,000 Da.

This functional glue matrix composition is lyophilized by filling the crosslinked copolymer composition prepared by steps 1 to 3 of the method for preparing a crosslinked copolymer composition described above in a petri dish, and then compressed to prepare a catechol-conjugated copolymer film. Manufacturing step 4; And after spraying water on at least one side of the copolymer film, it may be prepared including a step 5 of bonding and drying the film sheet on the sprayed surface.

Hereinafter, the present invention will be described in more detail with examples. The embodiments described below are intended to help the understanding of the present invention, but the scope of the present invention is not limited thereto.

Example 1  : Poly Vinyl-based  Copolymer Matrix, Catechol Graft  Copolymer, Bridged  Copolymer Composition and Preparation of Film Sheet Having Anti-Adhesion and Hemostatic Properties

(Production of Polyvinyl Copolymer Matrix)

2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) 3.8g, tert-butylmethacrylate (t-BMA) 0.85g, 2- molecular weight regulator 0.012 g of mercaptoethanol and 0.0065 g of 2,2'-azobis (2-methylpropionitrile), an initiator, were charged to a round bottom flask. Then, 40 mL of tetrahydrofuran was added to the flask, followed by reaction at 70 ° C. for 24 hours. After the reaction, after purification using 200 mL of heptane, 3.6 g of a polyvinyl copolymer matrix in powder form was obtained. 1H NMR structure analysis of the obtained polyvinyl copolymer matrix is shown in FIG. 2.

(Catechol graft copolymer in which a catechol derivative is bound to a polyvinyl copolymer matrix)

3 g of the obtained polyvinyl copolymer matrix and 1.1 g of 2-chloro-3 ', 4'-dihydroxyacetophenone were charged to a 150 mL round bottom flask, and 50 mL of ethanol was added thereto. Thereafter, the reaction was carried out at 80 ° C. for 48 hours, and then purified by 200 mL of cold tert butyl methyl ether to obtain 2.8 g of a catechol graft copolymer in powder form. 1H NMR structure analysis results of the obtained catechol graft copolymer is shown in FIG.

(Copolymer composition crosslinked through catechol graft copolymer and synthetic / natural polymer)

2.5 g of the obtained catechol graft copolymer and 1.5 g of chitosan were dissolved in TBS (Trizma based solution: pH 4.5), and 1 g of hydroxypropyl methyl cellulose was dissolved in TBS (Trizma based solution: pH 8.5), and then mixed in a 250 ml beaker. The solution was maintained at 50 ° C. for 12 hours, filled in Petri dish, and lyophilized to obtain a crosslinked copolymer composition. 1H NMR structure analysis results of the obtained crosslinked copolymer composition are shown in FIG. 4.

(Manufacture of film sheet having anti-adhesion and hemostatic properties)

0.1 g of hyaluronic acid having a molecular weight of about 230 kDa and 0.1 g of sodium alginate were maintained in 100 ml of distilled water at room temperature for 12 hours, and then dissolved in a Petri dish to be lyophilized to obtain a film sheet having anti-adhesion and hemostatic properties.

Experimental Example  One. Example  One ( Bridged  Copolymerization Composition ) And control

A photograph for visually showing the adhesion of the crosslinked copolymer composition prepared in Example 1 is shown in FIG. 5. As a result, the crosslinked copolymer composition showed adhesiveness.

After preparing the adhesive of the same weight in order to measure the adhesion of the control consisting of the cross-linked copolymer composition and Tachocomb prepared in Example 1, the adhesive of the composition of Example 1 and the control between the adhesive materials After applying each of the materials to adhere the adhesive materials, after 10 minutes to observe whether the adhesive materials were removed, the results are shown in FIG.

Experimental results, as shown in Figure 6, when comparing the adhesive strength of the two materials, it was confirmed that the adhesive strength of Example 1 is about 2 times stronger than the control group.

In order to measure the adhesive strength of the crosslinked copolymer composition prepared in Example 1 and the control over time, an adhesive material having the same weight was prepared, and then the adhesive material of the composition of Example 1 and the control material were adhered between the adhesive materials. After each coating to adhere the object to be bonded, after 10 minutes to observe whether the adhesion of the object to remove, and the results are shown in FIG. As a result, the adhesive force of Example 1 was confirmed to be stronger than the control group within a fast time.

Experimental Example  2. Example  One ( Bridged  Copolymerization Composition Haemostatic effect experiment

In order to confirm the hemostatic effect in the liver, kidney, and heart of the crosslinked copolymer composition prepared in Example 1, the tissue was artificially cut and bleeded, and the crosslinked copolymer composition prepared in Example 1 was attached thereto. The results are shown in Fig. As a result, it was confirmed that the crosslinked copolymer composition of Example 1 showed an effective hemostatic effect in liver, kidney, and heart.

In order to confirm that the crosslinked copolymer composition prepared in Example 1 exhibits a hemostatic effect in the vein, the vein was cut out and bleeded, and the crosslinked copolymer composition prepared in Example 1 was attached thereto. The results are shown in Fig. As a result, it was confirmed that the crosslinked copolymer composition of Example 1 effectively showed hemostasis in the vein.

Example  2. Catechol Graft  Preparation of Copolymer

15% by weight of copolymer of hydroxyethyl methacrylate and dimethylaminoethyl methacrylate polymer, 1.5% by weight of 4-dimethylaminopyridine (DMAP) and triethylamine, based on the total weight of the catechol graft copolymer to be prepared. After dissolving 1% by weight of (TEA) in 1,4-dioxene completely, 1.5% by weight of succinic and hydride (SA) was added. The mixed solution was stirred at room temperature for 24 hours, the solvent was removed, and then precipitated in cold tert-butyl methyl ether. The resulting precipitate was filtered and dried to give a white precipitate. The precipitate thus obtained was dissolved in N, N-dimethylformamide (DMF), followed by 1.5% by weight of N, N'-dicyclohexylcarbodiimide (DCC) and 1.5% by weight of N-hydroxysuccinimide (NHS). Added. Thereafter, 1.5% by weight of hydrocaffeic acid and 76.5% by weight of N, N-dimethylformamide (DMF) were added to the mixed solution. The mixed solution was stirred at room temperature for 24 hours, the solvent was removed, and then precipitated in cold tert-butyl methyl ether. The precipitate thus produced was filtered and dried to obtain a catechol graft copolymer as a white precipitate.

Example  3 to 6. Catechol Graft  Preparation of Copolymer

Example  3.- NH ₂ Catechol using a compound having a Graft  Copolymer production

5 g of dimethylaminoethyl methacrylate, 0.006 g of 2-mercaptoethanol as a molecular weight regulator and 0.0065 g of 2,2'-azobis (2-methylpropionitrile) as an initiator were charged to a round bottom flask. Then, 40 mL of tetrahydrofuran was added to the flask, followed by reaction at 70 ° C. for 12 hours. After the reaction, the mixture was purified using 200 mL of heptane, and then 4.8 g of a powdery copolymer was obtained.

4.8 g of the copolymer and 1.1 g of 2-chloro-3 ', 4'-dihydroxyacetophenone were charged to a 150 mL round bottom flask, followed by 40 mL of ethanol. Thereafter, the mixture was reacted at 80 ° C. for 48 hours, and purified with 200 mL of ether to obtain 5.7 g of a catechol graft copolymer in powder form.

Example  4. - OH Catechol using a compound having a Graft  Copolymer production

4 g of hydroxyethyl methacrylate or hydroxyethyl acrylate (compound having -OH at the end) and 0.2 g of 4-nitrophenyl chloroformate were charged into a round bottom flask, followed by 40 mL of dichloromethane. After the addition, the reaction was performed at room temperature for 24 hours. After the reaction, the mixture was purified using 200 mL of heptane, and then 4.0 g of an intermediate in which 4-nitrophenyl chloroformate was bound in powder form was obtained. (Preparation of a copolymer matrix before formation of a catechol group)

Subsequently, 4 g of the 4-nitrophenyl chloroformate-bound intermediate and 0.5 g of dopamine were charged into a round bottom flask, followed by addition of 40 mL of dimethyl sulfoxide, followed by reaction at room temperature for 24 hours, to 4-nitro bound. Phenyl chloroformate was removed and dopamine bound. After the reaction, the mixture was purified through dialesis for 2 days, and then lyophilized to obtain 4.2 g of a catechol graft copolymer.

Example  5.- OH Catechol using a compound having a Graft  Copolymer production

In order to form a carboxyl group on the compound having -OH at the end, and then to conjugate with a polymer having a catechol group, a copolymer in which hydroxyethyl methacrylate or hydroxyethyl acrylate is bonded ( 4 g, 4-dimethylaminopyridine and 0.03 g of triethylamine were completely dissolved in 40 mL of 1,4-dioxene. Next, 0.05 g of succinic and hydride was added. The mixed solution was stirred at room temperature for 24 hours, the solvent was removed, and then precipitated in cold tert-butyl methyl ether. The precipitate was filtered through a filter, dried, and the white precipitate was purified using 200 mL of heptane, followed by powdery succinic and hydra combined to give 4.0 g of an intermediate having a carboxyl group. (Copolymer matrix before catechol group formation) Produce)

Subsequently, 4 g of the intermediate in which the succinic and hydride were combined to form a carboxyl group, 0.5 g of dopamine, 0.01 g of dicyclohexylcarbodiimide and 0.05 g of 4-dimethylaminopyrimidine were charged into a round bottom flask, followed by dimethyl sulfoxide. Seed 40mL was added and reacted at room temperature for 24 hours. After the reaction, the mixture was purified through dialesis for 2 days, and then lyophilized to obtain 4.25 g of a catechol graft copolymer.

Example  6.- COOH Catechol using a compound having a Graft  Copolymer production

4 g of a tert butyl methacrylate-linked copolymer (compound having -COOH at the end) and a trifluoroacetic acid 0.1 g round bottom flask were charged. Then, 40 mL of dichloromethane was added, followed by reaction at room temperature for 24 hours.

After the reaction, the mixture was purified using 200 mL of heptane, and 4.0 g of a copolymer including carboxylate in powder form was obtained. (Preparation of a copolymer matrix before formation of a catechol group)

4 g of the copolymer containing the carboxylic acid and the dicyclohexylcarbodiimide 0.01g, 4-dimethylaminopyrimidine 0.05g and 0.5g of dopamine were charged into a round bottom flask, followed by adding 40 mL of dimethyl sulfoxide. After reaction at room temperature for 24 hours. After the reaction, the mixture was purified through dialesis for 2 days, and then lyophilized to obtain 4.25 g of a catechol graft copolymer.

Example  7 to 10. Example  Catechol using 3 to 6 Conjugation  Copolymer film and functionality Glue  Matrix Manufacturing

In order to prepare the catechol graft copolymers prepared in Examples 3 to 6 as the crosslinked copolymer composition, the catechol graft copolymers prepared in Examples 3 to 6 were each prepared at a concentration of 60 (w / w)%. After dissolving in TBS (pH 8.0) was maintained for 18 hours at 75 ℃ to prepare a crosslinked copolymer composition. Thereafter, the crosslinked copolymer composition was filled in petri dishes and lyophilized. The dried product was pressed up and down to form a flat film, thereby preparing a copolymer film conjugated with catechol.

Then, a suitable amount of water was sprayed on one or more sides of the copolymer film conjugated with the catechol and wetted, and then a PP film was attached to the wet surface. The water was then dried to obtain a functional glue matrix, a crosslinked product having flexibility.

Experimental Example  3. Example  7 to 10 Conjugation  The adhesion of the copolymer copolymer film

In order to compare and measure the adhesion of the control group consisting of the conjugated copolymer films prepared in Examples 7 to 10 and Tachocomb, the same weight of the target material was prepared, and then After the conjugated copolymer films of Examples 7 to 10 and the adhesive material of the control group were applied to each other to adhere the adhesive target materials, after 10 minutes, it was observed whether the adhesive target materials were dropped off, and the results were shown in FIG. 10. Shown in

Experimental results, as shown in Figure 10, it was found that the materials of each of Examples 7 to 10 are similar or stronger than the control group.

Adhesion results with time of the conjugated copolymer films prepared in Examples 7 to 10 are shown in FIG. 11.

Experimental results, as shown in Figure 11, was found to exhibit a similar or higher adhesion than the control within a short time.

Example 11 Preparation of Polyvinyl Copolymer Matrix, Catechol Graft Copolymer, and Crosslinked Copolymer Composition

(Copolymer in which main chain-forming compound is bonded to polyvinyl copolymer)

3 g of polyethylene glycol was dissolved in toluene as the main chain formable compound. Thereafter, 0.16 g of t-butylperoxybenzoate was dissolved in toluene and slowly added thereto, and maintained for 1 hour and 30 minutes. 3.8 g of 2-dimethylaminoethyl methacrylate (DMAEMA) and 0.85 g of tert-butylmethacrylate (t-BMA) were charged in a round bottom flask. I was. The reaction solution was reacted at 140 ° C. for 24 hours. After the reaction, after purification using 200 mL of heptane, 3.6 g of a copolymer matrix having a main chain formable compound bound to a polyvinyl copolymer in powder form was obtained.

(Catechol graft copolymer in which a catechol derivative is bonded to a copolymer matrix in which a main chain formable compound is bonded to a polyvinyl copolymer)

3 g of the copolymer matrix having a main chain-forming compound bonded to the obtained polyvinyl copolymer and 1.1 g of 2-chloro-3 ', 4'-dihydroxyacetophenone were charged into a 150 mL round bottom flask, followed by 50 mL of ethanol. Was added. Thereafter, the reaction was carried out at 80 ° C. for 48 hours, and then purified by 200 mL of cold tert-butyl methyl ether to obtain 2.8 g of a catechol graft copolymer in powder form.

1: film sheet
2: copolymer film conjugated with catechol

Claims (30)

A polyvinyl copolymer matrix comprising a polyvinyl copolymer or a copolymer in which a main chain formable compound is bonded to a polyvinyl copolymer, wherein the vinyl compounds are bonded; And
The catechol graft copolymer, characterized in that it comprises a catechol derivative grafted to the polyvinyl copolymer matrix. The method of claim 1,
The polyvinyl copolymer matrix is a catechol graft copolymer, characterized in that the compound of Formula 1:
[Chemical Formula 1]

In Formula 1,
X and Z are vinyl compounds,
X is greater than 0 and less than 100 wt% and Z is greater than 0 and less than 100 wt% with respect to the total weight of the polyvinyl copolymer copolymer. 3. The method of claim 2,
The vinyl compound is 2-hydroxyethyl methacrylate (HEMA, 2-hydroxyethyl methacrylate), 2-hydroxyethyl acrylate (HEA, 2-hydroxyethyl acrylate), 2-dimethylaminoethyl methacrylate (DMAEMA, 2 -(dimethylamino) ethyl methacrylate), 2-diethylaminoethyl methacrylate (DEAEMA, 2- (diethylamino) ethyl methacrylate), tert-butylmethacrylate (t-BMA, tert-butylmethacrylate), 2-aminoethyl 2-Aminoethyl methacrylate (AEM), methyl methacrylate, ethyl methacrylate, butyl methacrylate, isobutyl methacrylate, hexyl methacrylate, isodecyl methacrylate, lryl methacrylate, phenyl At least one polymer selected from methacrylate, methyl acrylate, isopropyl acrylate, isobutyl acrylate and octadecyl acrylate Catechol graft copolymer as set. 3. The method of claim 2,
General formula of Formula 1 is a catechol graft copolymer, characterized in that represented by the following formula (2):
(2)

In Formula 2, a is 20 to 2000,
Y is H, CH ₃ , CH ₂ CH ₃ Lt; / RTI >
R is either COO or CONH,
b is an integer from 0 to 5,
P is H, hydroxy (OH), amine (NH ₂ ), tertiary amine [N (CH ₃ ) ₂ , N (CH ₂ CH ₃ ) ₂ or N (CH ₂ CH ₂ CH ₃ ) ₂ ], CH _{3 ,} C (CH ₃ ) ₃ and C (CH ₂ CH ₃ ) ₃ . The method of claim 1,
The copolymer in which the main chain-forming compound is bonded to the polyvinyl-based copolymer is catechol graft copolymer, characterized in that:
(3)

In Formula 3,
A is a main chain formable compound,
X and Z are vinyl compounds,
X is more than 0 and less than 100% by weight and Z is more than 0 and less than 100% by weight relative to the total weight of the polyvinyl copolymer. 6. The method of claim 5,
The main chain formable compound,
At least one selected from polyethylene glycol, polypropylene oxide, polycaprolactone, polylactic acid, pluronic, polyglycoside, methoxy polyethylene glycol, polylactic glycol, polylactic and polyglycol Catechol graft copolymer, characterized in that. 6. The method of claim 5,
The vinyl compound,
2-hydroxyethyl methacrylate (HEMA, 2-hydroxyethyl methacrylate), 2-hydroxyethyl acrylate (HEA), 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate), 2-diethylaminoethyl methacrylate (DEAEMA, 2- (diethylamino) ethyl methacrylate), tert-butylmethacrylate (t-BMA, tert-butylmethacrylate), 2-aminoethyl methacrylate (AEM , 2-aminoethyl methacrylate), methyl methacrylate, ethyl methacrylate, butyl methacrylate, isobutyl methacrylate, hexyl methacrylate, isodecyl methacrylate, lauryl methacrylate, phenyl methacrylate, methyl Catechol, characterized in that the polymer is any one or more selected from acrylate, isopropyl acrylate, isobutyl acrylate and octadecyl acrylate. Soft copolymer. 6. The method of claim 5,
General structural formula of Formula 3 is a catechol graft copolymer, characterized in that represented by the following formula (4):
[Chemical Formula 4]

In Formula 4, a is 20 to 2000,
Y is H, CH ₃ , CH ₂ CH ₃ Lt; / RTI >
R is either COO or CONH,
b is an integer from 0 to 5,
P is H, hydroxy (OH), amine (NH ₂ ), tertiary amine [N (CH ₃ ) ₂ , N (CH ₂ CH ₃ ) ₂ or N (CH ₂ CH ₂ CH ₃ ) ₂ ], CH _{3 ,} C (CH ₃ ) ₃ and C (CH ₂ CH ₃ ) ₃ ,
The molecular weight of A is 200-50,000 Da. The method of claim 1,
The polyvinyl copolymer matrix,
2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) and tert-butyl methacrylate (t-BMA, tert-butylmethacrylate), containing a molecular weight of 1,000 to 100,000 grams per mole Catechol graft copolymer characterized in that. The method of claim 1,
Catechol graft copolymer, characterized in that the compound consisting of the formula
[Chemical Formula 5]

X is a polyvinyl copolymer matrix,
Y is a catechol derivative,
l: m is the weight ratio of X and Y, with respect to the total weight of the catechol graft copolymer, X is greater than 0 to less than 100% by weight and Y is greater than 0 to less than 100% by weight. The method of claim 1,
The catechol derivative,
2-chloro-3 ', 4'-dihydroxyacetophenone, 2-bromo-3', 4'-dihydroxyacetophenone, 2-iodide-3 ', 4'-dihydroxyacetophenone , Dopamine, caffeic acid, garlic acid, chlorogenic acid, (-)-epicatechin, (-)-epicatechin gallate, melanin, tannin, flavonoids, cyanidins, dihydroquercetin, oron, dihydromyricetin, delfinidine, Catechol graft copolymer, characterized in that any one or more selected from mycetin, quercetin, (-)-epicalocatechin-3-gallate, catechin, luteolin, norepinephrine and epinephrine. The method of claim 1,
The catechol derivative is a catechol graft copolymer, characterized in that the compound consisting of the formula
[Chemical Formula 6]

(7)

In the above formula (6) or (7)
L is Cl, Br or I,
n is an integer from 1 to 12. Adding a reaction solvent to the polyvinyl copolymer, reacting at 60 ° C. to 80 ° C. for at least 12 hours, and then purifying to prepare a polyvinyl copolymer copolymer; And
And a step 2 of mixing the polyvinyl copolymer matrix prepared in Step 1, the catechol derivative, and the organic solvent having 1 to 7 carbon atoms and reacting at 20 ° C. to 80 ° C. for at least 24 hours. Method for producing a catechol graft copolymer. The method of claim 13,
The polyvinyl copolymer of the step 1,
2-hydroxyethyl methacrylate (HEMA, 2-hydroxyethyl methacrylate), 2-hydroxyethyl acrylate (HEA), 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate), 2-diethylaminoethyl methacrylate (DEAEMA, 2- (diethylamino) ethyl methacrylate), tert-butylmethacrylate (t-BMA, tert-butylmethacrylate), 2-aminoethyl methacrylate (AEM , 2-aminoethyl methacrylate), methyl methacrylate, ethyl methacrylate, butyl methacrylate, isobutyl methacrylate, hexyl methacrylate, isodecyl methacrylate, lauryl methacrylate, phenyl methacrylate, methyl At least one polymer selected from acrylate, isopropyl acrylate, isobutyl acrylate and octadecyl acrylate is characterized in that the copolymerized Tekol graft copolymer production method. The method of claim 13,
The reaction solvent is a method of producing a catechol graft copolymer, characterized in that any one of tetrahydrofuran, toluene, benzene, dichloromethane and ethanol. The method of claim 13,
Method for producing a catechol graft copolymer, characterized in that the polyvinyl copolymer matrix is any one of the following 1-3:
1) Molecular weight of 1,000 to 100,000 grams per mole of 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) combined with tert-butylmethacrylate (t-BMA) Copolymers;
2) a copolymer having a molecular weight of 1,000 to 100,000 grams per mole of 2-hydroxyethyl methacrylate (HEMA); or
3) Copolymer having a molecular weight of 1,000 to 100,000 grams per mole in which tert-butylmethacrylate (t-BMA, tert-butylmethacrylate) is bonded. The method of claim 13,
The catechol derivative,
2-chloro-3 ', 4'-dihydroxyacetophenone, 2-bromo-3', 4'-dihydroxyacetophenone, 2-iodide-3 ', 4'-dihydroxyacetophenone , Dopamine, caffeic acid, garlic acid, chlorogenic acid, (-)-epicatechin, (-)-epicatechin gallate, melanin, tannin, flavonoids, cyanidins, dihydroquercetin, oron, dihydromyricetin, delfinidine, Method for producing a catechol graft copolymer, characterized in that any one or more selected from mycetin, quercetin, (-)-epicalocatechin-3-gallate, catechin, luteolin, norepinephrine and epinephrine. The method of claim 13,
The catechol graft copolymer is
Method for producing a catechol graft copolymer, characterized in that the compound consisting of the formula (5).
[Chemical Formula 5]

X is a polyvinyl copolymer matrix,
Y is a catechol derivative,
1: m is a weight ratio of X and Y, with respect to the total weight of the catechol graft copolymer, X is greater than 0 to less than 100% by weight, and Y is greater than 0 to less than 100% by weight. Catechol graft copolymers according to any one of claims 1 to 12; And
Crosslinked copolymer composition comprising a; synthetic / natural polymer crosslinked with the catechol graft copolymer. 20. The method of claim 19,
The synthetic / natural polymer,
Hyaluronic acid, sodium alginate, potassium alginate, chitosan, collagen, lysine (Lysine), polyethyleneimine (PEI, polyethyleneimine), glutathione (GSH), dextran, carboxymethyl cellulose (CMC) Hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC, hydroxypropyl cellulose), glucose, gum arabic, ethanol, sodium casein, agar powder, glycerin, phthalic acetate cellulose, stearic acid, sodium carboxymethyl cellulose, Carboxymethyl Cellulose Calcium, Methyl Cellulose Sodium, Methyl Cellulose, Purified Shellac, Ethylcelluose, Sodium Alginate, Sodium Lauryl Sulfate (SLS), Magnesium (Maganesium), Microcrystalline Cellulose, Starch , Hydroxycellulose, hydroxypropyl starch, Polyvinyl alcohol, hydroxymethyl cellulose, sorbitol, hydroxyethyl starch, hydroxyethyl starch, propo, polyethylene glycol (PEG), and Pluronic (Pluronic), characterized in that any one selected from Crosslinked copolymer composition. The method of claim 20,
Crosslinked copolymer composition, characterized in that the molecular weight of the synthetic / natural polymer is 1,000 ~ 4,000,000 Da. Polyvinyl copolymer matrix by adding 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) and tert-butylmethacrylate (t-BMA, tert-butylmethacrylate), molecular weight regulator and initiator Step 1 to prepare;
Preparing a catechol graft copolymer to which the catechol derivative is grafted by reacting the catechol derivative with the polyvinyl copolymer matrix prepared in step 1; And
A method for producing a crosslinked copolymer composition comprising the step 3 of preparing a crosslinked copolymer composition by crosslinking the catechol graft copolymer prepared in step 2 with a synthetic / natural biopolymer. 23. The method of claim 22,
In the step 1,
The polyvinyl copolymer matrix,
0.15 to 1 part by weight of a molecular weight modifier based on 100 parts by weight of 2-dimethylaminoethyl methacrylate (DMAEMA, 2- (dimethylamino) ethyl methacrylate) and tert-butylmethacrylate (t-BMA); Method for producing a crosslinked copolymer composition, characterized in that it is prepared by adding 0.05 to 0.3 parts by weight of initiator. 23. The method of claim 22,
In step 2 above,
Process for producing a crosslinked copolymer composition, characterized in that the reaction for 24 to 50 hours at a temperature of 60 ℃ to 90 ℃ in ethanol solvent. 23. The method of claim 22,
In step 3 above,
Method for producing a crosslinked copolymer composition, characterized in that the reaction for 10 to 12 hours at a temperature of 50 ℃ to 60 ℃ in a TBS (Trizma based solution) solvent. A catechol-conjugated copolymer film in the form of a film freeze-dried the crosslinked copolymer composition according to claim 19; And
Functional glue matrix composition comprising a film sheet bonded to at least one of the upper and lower surfaces of the copolymer film. 27. The method of claim 26,
The film sheet is a functional glue matrix composition comprising a component having anti-adhesion or hemostatic properties. 28. The method of claim 27,
The film sheet,
Hyaluronic acid, sodium alginate, potassium alginate, chitosan, collagen, lysine (Lysine), polyethyleneimine (PEI, polyethyleneimine), glutathione (GSH), dextran, carboxymethyl cellulose (CMC) Hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC, hydroxypropyl cellulose), glucose, gum arabic, ethanol, sodium casein, agar powder, glycerin, phthalic acetate cellulose, stearic acid, sodium carboxymethyl cellulose, Carboxymethyl Cellulose Calcium, Methyl Cellulose Sodium, Methyl Cellulose, Purified Shellac, Ethylcelluose, Sodium Alginate, Sodium Lauryl Sulfate (SLS), Magnesium (Maganesium), Microcrystalline Cellulose, Starch , Hydroxycellulose, hydroxypropyl starch, Polyvinyl alcohol, hydroxymethyl cellulose, sorbitol, hydroxyethyl starch, propo, polyethyleneglycol (PEG) and Pluronic are composed of at least one composition Functional glue matrix composition, characterized in that. 29. The method of claim 28,
Functional glue matrix composition, characterized in that the molecular weight of the film sheet is 1,000 ~ 4,000,000 Da. 27. The method of claim 26,
The film sheet is
A functional glue matrix composition comprising hyaluronic acid, sodium alginate or potassium alginate.

Images